AbCellera: EU Joint Procurement for up to 220,000 doses of bamlanivimab/etesevimab

AbCellera Biologics Inc.

EC and Lilly agree to supply up to 220,000 doses of bamlanivimab plus etesevimab for COVID-19 in EU/EEA patients 12+ at risk.
Therapy neutralizes Delta variant causing >95% of new EU/EEA infections.
In US, therapy treated >535,000 patients; estimated 25,000 hospitalizations and 10,000 lives saved.
Participating EU/EEA countries can purchase directly from Lilly after national or EU authorization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.